A digitally enhanced pulmonary rehabilitation approach for COPD during COVID-19 using myCOPD

Stokes, J. G.; Savage, Kate

doi:10.1183/13993003.congress-2021.pa616

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EAG’s search did not identify any clinical studies that were not stated in the company’s submission, but a further five published RWE papers were identified by the EAG’s searches, including an additional three RWE settings (Kent [ 19 ], Mid and South Essex [ 20 ] and Dorset [ 21 ]).…”

Section: Review Of Clinical and Economic Evidencementioning

confidence: 99%

myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology

Davies

Chappell

Wang

et al. 2023

Appl Health Econ Health Policy

View full text Add to dashboard Cite

myCOPD is a digital tool designed for people to manage their chronic obstructive pulmonary disease (COPD). It requires a device with an internet connection and incorporates tools for education, self-management, symptom tracking and pulmonary rehabilitation (PR). myCOPD was selected for medical technologies guidance by the UK National Institute for Health and Care Excellence (NICE) in 2020. The External Assessment Group (EAG) critiqued the company’s submission. The evidence comprised four clinical studies (three randomised controlled trials [RCTs] and one observational study) and real-world evidence from 22 documents. The RCTs had small sample sizes, limiting the power to detect statistically significant differences and to match patient characteristics across arms. The company produced two de novo models for two subgroups of people with COPD; people discharged from hospital with acute exacerbation of COPD (AECOPD) and people referred for PR. After the EAG updated input parameters and adjusted the model structures, cost savings of £86,297 per clinical commissioning group (CCG) compared with standard care were estimated for the AECOPD population, with myCOPD predicted to be cost saving in 74% of iterations. Cost savings of £22,779 per CCG were estimated for the PR population (with the assumption that the CCG had an existing myCOPD licence), with myCOPD predicted to be cost saving in 86% of the iterations. The Medical Technologies Advisory Committee concluded that although myCOPD has the potential to help manage COPD in adults, further evidence is required to address uncertainties in the current evidence base. NICE published this as Medical Technology Guidance 68 (National Institute for Health and Care Excellence (NICE). myCOPD for managing chronic obstructive pulmonary disease. 2022. Available at: https://www.nice.org.uk/guidance/mtg68/ ). Supplementary Information The online version contains supplementary material available at 10.1007/s40258-023-00811-x.

show abstract

Section: Review Of Clinical and Economic Evidencementioning

confidence: 99%